Tuberculosis
Also known as: TB, Mycobacterium tuberculosis infection
Tuberculosis is a potentially serious infectious disease primarily affecting the lungs, caused by the bacterium Mycobacterium tuberculosis. TB spreads through airborne droplets when an infected person coughs, sneezes, or speaks. While latent TB infection causes no symptoms and is not contagious, active TB disease can be fatal without proper treatment, which typically involves a months-long course of antibiotics.
Last updated November 10, 2026
Understanding Tuberculosis
Tuberculosis is an infection with Mycobacterium tuberculosis, a slow-growing bacterium that is inhaled in tiny droplets coughed out by someone with active lung disease. Worldwide it is again the leading infectious cause of death: the World Health Organization estimates that 10.8 million people fell ill with TB in 2023 and 1.25 million died, and roughly a quarter of the world's population carries the bacterium in a dormant, latent state. In the United States the disease is uncommon but rising, with about 10,300 cases reported in 2024, the most since 2011, and an estimated 13 million people living with latent infection. About three quarters of US cases occur in people born outside the country and most represent reactivation of an infection acquired years earlier. Without treatment, roughly 5 to 10 percent of people with latent infection progress to active disease in their lifetime, half of them within the first two years.
After inhalation, the bacteria are engulfed by immune cells in the lung, which wall them off in clusters called granulomas. In most people this standoff holds indefinitely; the person has no symptoms, cannot infect anyone, and tests positive only on a skin test or interferon-gamma release assay. Active disease occurs when the balance tips, most often because immunity has weakened: HIV raises the risk roughly 16-fold, and diabetes, kidney failure, undernutrition, smoking, heavy drinking, silicosis, TNF-inhibitor drugs, steroids and simple aging all contribute. Active pulmonary TB destroys lung tissue slowly, producing the cough, weight loss, night sweats and blood-streaked sputum that develop over weeks to months, and the person becomes infectious. About one in five US cases involves sites outside the lungs (lymph nodes, pleura, bone, kidneys, the lining of the brain), which are not contagious. Untreated, about half of people with active pulmonary TB die within a few years, a quarter recover and a quarter remain chronically ill and infectious.
TB is treated with antibiotics, for months, and nothing else works. The 2016 ATS/CDC/IDSA guideline standard for drug-susceptible disease is two months of isoniazid, rifampin, pyrazinamide and ethambutol followed by four months of isoniazid and rifampin, six months in all; in a 2,516-person trial (NEJM 2021), a four-month rifapentine-moxifloxacin regimen was non-inferior and the CDC now allows it for people aged 12 and over. Latent infection is treated with shorter, better-tolerated courses: four months of daily rifampin, which in a 6,063-person trial had higher completion and less liver toxicity than nine months of isoniazid, or 12 once-weekly doses of isoniazid plus rifapentine. Multidrug-resistant TB is now treated with six-month all-oral regimens built on bedaquiline, pretomanid and linezolid. Treatment success exceeds 85 percent when the course is completed, and adherence is the single factor that determines it: missed doses let the slowest-growing bacteria survive and select for resistance. US health departments provide the drugs free and offer directly observed therapy, in person or by video. Monitoring includes liver tests (alt, ast, bilirubin), sputum cultures at two months and vision checks on ethambutol.
Supplements have a narrow, defined place in TB care, and several common ones interfere with the drugs. Pyridoxine (vitamin B6) at 25 to 50 mg daily is prescribed with isoniazid to prevent nerve damage in people at risk; it is standard care. Vitamin D deficiency is common in TB and worth correcting, but a meta-analysis of 1,850 trial participants found no overall speeding of sputum clearance. Zinc and vitamin A trials showed no benefit, and Cochrane found no micronutrient that improves outcomes, whereas adequate food does (a 2023 Indian trial of food support cut TB among household contacts by about 40 percent). Milk thistle and N-acetylcysteine have small trials suggesting less drug-induced liver injury. The interactions matter more than the benefits: rifampin lowers blood levels of many drugs and St. John's wort does the same; isoniazid blocks the breakdown of tyramine and histamine, so aged cheese, red wine and spoiled fish can cause flushing and headache; kava, comfrey, high-dose niacin, green tea extract and red yeast rice add liver strain; aluminum antacids reduce isoniazid absorption; and calcium, magnesium, iron and zinc bind the fluoroquinolones used in newer regimens.
The most common mistake is stopping early. Cough, fever and appetite usually recover within two to eight weeks, long before the bacteria are gone, and people who feel well drift away from a regimen that causes nausea, orange urine and daily inconvenience. The result is relapse, often with resistant bacteria that need longer, more toxic and more expensive treatment. If you are struggling, say so: the dose timing can be changed, nausea treated, a pill organizer or phone reminder set up, and observed therapy arranged. The second mistake is hiding side effects. Nausea with vomiting, dark urine, yellow eyes, abdominal pain, numb or burning feet, or any change in vision needs same-day contact with the clinic, because these are the signs of liver toxicity, neuropathy and eye damage that are reversible when caught and serious when ignored.
At a Glance
- Common symptoms
- Persistent cough lasting three weeks or more, Coughing up blood or sputum, Chest pain or pain with breathing
- Main treatments
- Standard four-drug regimen (isoniazid, rifampin, ethambutol, pyrazinamide) for 6-9 months, Direct observed therapy to ensure adherence, Shorter regimens for latent TB infection
- Category
- Infectious · About 10 million people develop active TB worldwide each year; approximately 8,000 cases in the US annually
- See a doctor if
- Cough lasting more than three weeks, especially with blood
Symptoms
Causes
- Infection with Mycobacterium tuberculosis bacteria
- Airborne transmission through respiratory droplets
- Reactivation of latent TB infection when the immune system weakens
Risk Factors
- Close contact with someone who has active TB
- Weakened immune system from HIV, diabetes, or immunosuppressive medications
- Living in or traveling to areas with high TB prevalence
- Healthcare workers exposed to TB patients
- Living in crowded or poorly ventilated conditions
- Substance abuse or homelessness
Diagnosis
- Tuberculin skin test (Mantoux test)
- Interferon-gamma release assay blood test
- Chest X-ray for signs of active disease
- Sputum smear microscopy and culture
- GeneXpert rapid molecular test for TB and drug resistance
Treatment
- Standard four-drug regimen (isoniazid, rifampin, ethambutol, pyrazinamide) for 6-9 months
- Direct observed therapy to ensure adherence
- Shorter regimens for latent TB infection
- Second-line drugs for drug-resistant TB
- Nutritional support and rest during treatment
Natural remedies for tuberculosis: what the evidence says
Ranked by the strength of human evidence for tuberculosis specifically. These sit alongside medical care, not in place of it.
Vitamin B6 (Pyridoxine)
Strong evidenceIsoniazid binds pyridoxine and causes a dose-related peripheral neuropathy, numbness and burning in the feet, in up to 20 percent of people with risk factors if it is not supplemented. Prophylactic pyridoxine at 25 to 50 mg daily prevents it and is recommended in the ATS/CDC/IDSA treatment guideline for anyone with diabetes, HIV, kidney failure, alcohol use disorder, undernutrition, seizure disorder or pregnancy, and is widely given to everyone on isoniazid. Pyridoxine is also the specific antidote to isoniazid overdose.
- Studied dose
- 25 to 50 mg pyridoxine once daily for the full duration of isoniazid treatment, as prescribed by the TB clinic.
- Cautions
- Doses above 200 mg daily for months can themselves cause neuropathy, so do not add extra B6 on top of the prescribed amount. High-dose B6 reduces the effect of levodopa taken without carbidopa.
Vitamin D
Preliminary evidenceLow vitamin D is found in most people with active TB, and vitamin D helps immune cells produce antimicrobial peptides in the laboratory. In practice the trials are disappointing: a 2019 individual-participant meta-analysis of 8 randomized trials (1,850 patients) found no overall acceleration of sputum culture conversion with high-dose vitamin D, with a possible benefit only in the multidrug-resistant subgroup, and a 3-year trial in 8,851 Mongolian schoolchildren found 14,000 IU weekly did not prevent TB infection. Correcting a documented deficiency remains sensible for bone and muscle health, particularly because rifampin lowers vitamin D levels further.
- Studied dose
- 1,000 to 2,000 IU vitamin D3 daily if a blood level is below 20 ng/mL, rechecked after 3 months; the trial mega-doses are not needed.
- Cautions
- Avoid above 4,000 IU daily without monitoring. Vitamin D raises calcium, so use care in sarcoidosis, kidney stones and with thiazide diuretics.
N-Acetylcysteine
Preliminary evidenceIn a randomized trial of 60 adults aged 60 and over starting standard TB treatment in Iran, 600 mg of N-acetylcysteine twice daily for the first two weeks prevented drug-induced liver injury entirely (0 percent versus 37.5 percent in the control group). The trial was small, short and unblinded, and has not been repeated at scale, so NAC cannot replace liver monitoring. It is reasonable to discuss with the TB clinic for people at high risk of hepatotoxicity.
- Studied dose
- 600 mg N-acetylcysteine twice daily, studied for the first 2 weeks of treatment.
- Cautions
- Sulfur smell and nausea are common; rare bronchospasm in asthma. Tell the clinic before starting so that it is not mistaken for a drug reaction, and do not use it to justify alcohol.
Milk Thistle (Silymarin)
Preliminary evidenceIn a 55-person randomized placebo-controlled trial in Thailand, silymarin 140 mg three times daily for the first four weeks of TB treatment reduced drug-induced liver injury from 32 percent to about 4 percent, and a 2019 meta-analysis of randomized trials found a lower rate of liver injury and lower ALT with silymarin. The trials are small, of uneven quality and mostly from single centers, and a large confirmatory trial is lacking. It does not help the drugs work and is not a reason to skip liver tests.
- Studied dose
- 140 mg standardized silymarin three times daily during the first 4 to 8 weeks of treatment, when liver injury is most likely.
- Cautions
- Mild laxative effect; avoid with allergy to ragweed or daisies. Silymarin may modestly alter CYP2C9 and CYP3A4 activity, so mention it to the prescriber when you take warfarin, diabetes drugs or HIV medication alongside TB treatment.
What matters day to day
- Take the drugs at the same time every day and use a pill organizer or phone alarm, or accept observed therapy: completion, not the choice of regimen, is what predicts success, and each missed week raises the risk of relapse with resistant bacteria.
- Stop drinking alcohol for the whole course: alcohol multiplies the liver toxicity of isoniazid, rifampin and pyrazinamide, and heavy drinking is one of the strongest predictors of treatment failure and death.
- Eat enough to regain weight: undernutrition (a body mass index under 18.5) roughly doubles the risk of dying during TB treatment, and a trial of food support for household contacts in India reduced new TB cases by about 40 percent.
- Stop smoking: smokers are about twice as likely to develop active TB, have more lung damage, convert their sputum more slowly and relapse more often than non-smokers on the same drugs.
- For the first two weeks of treatment, stay home, sleep in a separate well-ventilated room and wear a mask around others: infectiousness falls sharply once effective treatment starts, and the health department will tell you when you are cleared.
- If you take rifampin or rifapentine, use a non-hormonal contraceptive for the course and one month after: rifamycins make birth control pills, patches, rings and implants unreliable, and they also weaken many other medicines, so bring your full drug list to every visit.
Prevention
- BCG vaccine in high-prevalence countries
- Contact tracing and treatment of latent TB infection
- Infection control measures in healthcare facilities
- Improving ventilation in congregate settings
When to See a Doctor
- Cough lasting more than three weeks, especially with blood
- Unexplained weight loss with night sweats
- Known exposure to someone with active TB
- Positive TB skin or blood test
Frequently Asked Questions
References
- Nahid P, Dorman SE, Alipanah N, et al.. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases (2016)
- Dorman SE, Nahid P, Kurbatova EV, et al.. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. New England Journal of Medicine (2021)
- Menzies D, Adjobimey M, Ruslami R, et al.. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. New England Journal of Medicine (2018)
- World Health Organization. Global Tuberculosis Report 2024 (2024)
- Jolliffe DA, Ganmaa D, Wejse C, et al.. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data. European Respiratory Journal (2019)
- Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. Cochrane Database of Systematic Reviews (2016)
- Bhargava A, Bhargava M, Meher A, et al.. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet (2023)
- Baniasadi S, Eftekhari P, Tabarsi P, et al.. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. European Journal of Gastroenterology and Hepatology (2010)
- Luangchosiri C, Thakkinstian A, Chitphuk S, et al.. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complementary and Alternative Medicine (2015)
- Centers for Disease Control and Prevention. Tuberculosis (TB) (2025)View source
Related Conditions
Related Reading
Have questions about Tuberculosis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.